Xencor, Inc.

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Retrieved on: 
星期日, 十二月 12, 2021
Medical Devices, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Oncology, Forward-looking statement, U.S. Securities and Exchange Commission, NK, Protein, NHL, AES, Clinical trial, Premedication, Neurotoxicity, B-cell lymphoma, Follicular lymphoma, CR, Private Securities Litigation Reform Act, Degenerative disease, Mantle cell lymphoma, ORR, Lenalidomide, CD20, Cancer, Hypophosphatemia, Janssen Pharmaceuticals, NASDAQ, Janssen, Thrombocytopenia, Neutropenia, Anemia, Lymphocytopenia, Fatigue, Non-Hodgkin lymphoma, Annual report, Form 10-K, Safety, Cytokine, Patient, Johnson & Johnson, Data, Tafasitamab, DLBCL, Therapy, Security (finance), CD3, CRS, CD28, ASH, Cytokine release syndrome, Trial of the century, EST, Technology, Society, Vaccine, Pharmaceutical industry, Fine chemical, Part, Plamotamab, Xencor, Inc., PLAMOTAMAB, XENCOR, INC.

A third part, Part C, was added to establish a step-up dosing regimen with higher, flat and less frequent dosing.

Key Points: 
  • A third part, Part C, was added to establish a step-up dosing regimen with higher, flat and less frequent dosing.
  • In Part C of the study, patients had generally more advanced disease and poorer responses to prior therapy.
  • Plamotamab is currently being evaluated in a Phase 1 clinical study for the treatment of patients with CD20-expressing hematologic malignancies, including NHL.
  • Preliminary safety and anti-tumor activity from the Phase 1 study indicates that plamotamab is generally well tolerated and demonstrates encouraging clinical activity as a monotherapy.

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Retrieved on: 
星期日, 十一月 21, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Patient, Private Securities Litigation Reform Act, Security (finance), Safety, Degenerative disease, Geography, Cell, Protein, Technology, Forward-looking statement, Achievement, MD, Cancer, Autoimmunity, Pharmacokinetics, U.S. Securities and Exchange Commission, Therapy, Annual report, CD19, Cytokine, Twitter, Research, Form 10-K, Immune system, LinkedIn, Multimedia, NASDAQ, Vaccine, Xencor, Inc., Zenas BioPharma, XENCOR, INC., ZENAS BIOPHARMA

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (Zenas), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab.

Key Points: 
  • Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (Zenas), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab.
  • Xencor demonstrated through early-stage clinical studies that obexelimab effectively inhibits B-cell function without depleting the cells and generates an encouraging treatment effect in patients with multiple autoimmune diseases.
  • Zenas will have sole responsibility for advancing the research, development, regulatory and commercial activities of obexelimab worldwide.
  • For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn .

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Retrieved on: 
星期五, 十一月 12, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Solar cycle 4, SITC, CXCL3, Cancer, Biopsy, Partial, CXCL8, Private Securities Litigation Reform Act, Form 10-K, Observation, Solar cycle 18, Neoplasm, PSA, Cytokine, Therapeutic index, Prostate cancer, Clinical trial, MCRPC, Abdominal wall, Security (finance), NASDAQ, CD8, Technology, Clinical Ovarian Cancer & Other Gynecologic Malignancies, RCC, Society, Trial of the century, Nivolumab, Serum, PD-1, Renal cell carcinoma, Forward-looking statement, CRPC, Annual report, Protein, U.S. Securities and Exchange Commission, IL-6, Large-cell lung carcinoma, Therapy, Degenerative disease, History, Pharmacodynamics, Prostate-specific antigen, Atrial fibrillation, Immunotherapy, Pancreas, IL-8, Patient, Melanoma, RECIST, Vaccine, Medical imaging, Pharmaceutical industry, Vudalimab (XmAb®717), Xencor, Inc., VUDALIMAB (XMAB®717), XENCOR, INC.

Dual targeting of these checkpoints through a bispecific antibody with a differentiated tolerability profile could meet an important unmet clinical need.

Key Points: 
  • Dual targeting of these checkpoints through a bispecific antibody with a differentiated tolerability profile could meet an important unmet clinical need.
  • We are now enrolling a Phase 2 study of vudalimab for patients with metastatic castration-resistant prostate cancer, as a monotherapy or in combination, depending on molecular subtype.
  • Baseline serum levels of the cytokines IL-6, IL-8 and IL-10 trended lower in patients who achieved a response on study.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting

Retrieved on: 
星期四, 十一月 4, 2021
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, CLL, B-cell lymphoma, Cytokine release syndrome, NHL, CD20, Technology, Cancer, Annual report, CRS, Security (finance), U.S. Securities and Exchange Commission, Patient, NASDAQ, Cytokine, Part, Private Securities Litigation Reform Act, CD28, ORR, ASH, Degenerative disease, Neurotoxicity, Forward-looking statement, Protein, CD3, Trial of the century, Form 10-K, Non-Hodgkin lymphoma, Follicular lymphoma, Lymphoid leukemia, Chronic lymphocytic leukemia, Therapy, Premedication, Society, Vaccine, Pharmaceutical industry, Plamotamab, Xencor, Inc., PLAMOTAMAB, XENCOR, INC.

The accepted abstract with data from the study is available through the ASH website .

Key Points: 
  • The accepted abstract with data from the study is available through the ASH website .
  • At data cut off on July 1, 2021, 80 patients with relapsed or refractory non-Hodgkins lymphoma (NHL) had received doses of plamotamab.
  • Plamotamab is currently being evaluated in a Phase 1 clinical study for the treatment of patients with CD20-expressing hematologic malignancies, including NHL and CLL.
  • Preliminary safety and anti-tumor activity from the Phase 1 study indicated that plamotamab was generally well tolerated and demonstrated encouraging clinical activity as a monotherapy.

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

Retrieved on: 
星期三, 十一月 3, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Event, Lung, Immunotherapy, Technology, Poster, Cancer, Merkel-cell carcinoma, Annual report, Neoplasm, CRS, Security (finance), U.S. Securities and Exchange Commission, Patient, NASDAQ, Cytokine, Investor, Private Securities Litigation Reform Act, NETS, Lymphocytopenia, Squamous cell carcinoma, Degenerative disease, PD-1, Vomiting, Wilms' tumor, SSTR2, Forward-looking statement, Protein, CD3, Clinical trial, Biomarker, Pancreas, Form 10-K, GEP-NET, Therapy, Ki-67 (protein), Incidence, Pharmaceutical industry, Vaccine, Tidutamab, Xencor, Inc., TIDUTAMAB, XENCOR, INC.

The data will be presented during the North American Neuroendocrine Tumor Societys 2021 Multidisciplinary NET Medical Virtual Symposium (NANETS).

Key Points: 
  • The data will be presented during the North American Neuroendocrine Tumor Societys 2021 Multidisciplinary NET Medical Virtual Symposium (NANETS).
  • In addition to the poster, these results will be presented during the Clinical Abstracts session, which begins at 1:25 p.m.
  • Dosing in the study included a lower priming dose, followed by a higher repeated dose on subsequent dosing days.
  • Tidutamab was generally well tolerated at the 0.3/1.0 mcg/kg dose identified for the expansion portion of the study.

Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies

Retrieved on: 
星期一, 十月 4, 2021
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Hospitals, Clinical Trials, Janssen Pharmaceuticals, Annual report, CD28, CD20, Security (finance), Degenerative disease, Therapy, Investor, Cytokine, Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, Cancer, Patient, CD3, NHL, Janssen, Form 10-K, CLL, Trial of the century, Technology, Johnson & Johnson, Hart–Scott–Rodino Antitrust Improvements Act, Forward-looking statement, B-cell lymphoma, Non-Hodgkin lymphoma, Lenalidomide, Chronic lymphocytic leukemia, Protein, Vaccine, Pharmaceutical industry, Plamotamab, XmAb® CD28 Bispecific Antibodies, Xencor, Inc., PLAMOTAMAB, XMAB® CD28 BISPECIFIC ANTIBODIES, XENCOR, INC.

Plamotamab is a CD20 x CD3 XmAb bispecific antibody and is currently completing a Phase 1 dose-escalation study in patients with CD20-expressing hematologic malignancies.

Key Points: 
  • Plamotamab is a CD20 x CD3 XmAb bispecific antibody and is currently completing a Phase 1 dose-escalation study in patients with CD20-expressing hematologic malignancies.
  • Under the terms of the agreement, Janssen will receive worldwide exclusive development and commercialization rights to plamotamab, whether as a monotherapy or in combination regimens.
  • Plamotamab is an investigational tumor-targeted XmAb bispecific antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3).
  • Xencor announced its first collaboration with Janssen to discover a CD28 bispecific antibody against an undisclosed prostate tumor target in 2020.

Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting

Retrieved on: 
星期五, 十月 1, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Annual report, Poster, Security (finance), Degenerative disease, CD5, Therapy, Cytokine, TGF beta receptor 2, Investor, Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, Patient, Form 10-K, Prostate cancer, MCRPC, Company, Immunotherapy, PD-1, Trial of the century, Society, Therapeutic index, Technology, Forward-looking statement, Renal cell carcinoma, Protein, Vaccine, Vudalimab (XmAb®717), Xencor, Inc., VUDALIMAB (XMAB®717), XENCOR, INC.

Posters will be archived under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .

Key Points: 
  • Posters will be archived under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Vudalimab (XmAb717) is an XmAb bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation.
  • In preclinical studies, dual blockade of PD-1 and CTLA-4 with vudalimab significantly enhanced T cell proliferation and activation, and anti-tumor activity in vivo.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.

Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

Retrieved on: 
星期四, 五月 27, 2021
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Life sciences, Clinical medicine, Immunology, Biotechnology, Monoclonal antibody, Biopharmaceutical, Antibody, Vaccine, Cytokine, GSK2831781, Antibody Solutions, Xtend™ XmAb® Fc Technology, Cytotoxic XmAb® Fc Technology, Xencor, Inc., XTEND™ XMAB® FC TECHNOLOGY, CYTOTOXIC XMAB® FC TECHNOLOGY, XENCOR, INC.

Though the vaccine rollout is underway, antibody treatments remain an important therapeutic measure to reduce the number of hospitalizations and deaths due to COVID-19."

Key Points: 
  • Though the vaccine rollout is underway, antibody treatments remain an important therapeutic measure to reduce the number of hospitalizations and deaths due to COVID-19."
  • Vir and GSK are evaluating sotrovimab in an extensive ongoing clinical development program.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.

Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

Retrieved on: 
星期二, 五月 25, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Xtend™ XmAb® Fc Technology, Xencor, Inc., XTEND™ XMAB® FC TECHNOLOGY, XENCOR, INC.

SARS-CoV-2 mAb Duo was discovered by researchers at The Rockefeller University and was subsequently licensed by Bristol Myers Squibb.

Key Points: 
  • SARS-CoV-2 mAb Duo was discovered by researchers at The Rockefeller University and was subsequently licensed by Bristol Myers Squibb.
  • This reflects the potential of Xencors XmAb protein engineering platforms to enhance the therapeutic performance of novel antibody candidates.
  • Xencors Xtend XmAb Fc domains have been shown to increase circulating half-life by increasing binding affinity to the receptor FcRn.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.

Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

Retrieved on: 
星期三, 四月 28, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Immunology, Medicine, Branches of biology, T cells, Regulatory T cell, Autoimmunity, Autoimmune disease, Immune system, XmAb®564, Xencor, Inc., XMAB®564, XENCOR, INC.

Tregs prevent autoimmunity by suppressing other immune cells from attacking normal tissue; however, in many autoimmune diseases, Tregs become dysregulated.

Key Points: 
  • Tregs prevent autoimmunity by suppressing other immune cells from attacking normal tissue; however, in many autoimmune diseases, Tregs become dysregulated.
  • An existing approach to restore normal immune activity and improve outcomes for patients has been to activate Tregs with IL-2 provided therapeutically at low doses.
  • Currently, 21 candidates engineered with Xencor\'s XmAb\xc2\xae technology are in clinical development internally and with partners.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date.